Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
106-120 of 4506 results
H3 Biomedicine, Foundation Medicine extend precision oncology collaboration
H3 Biomedicine has extended its multi-year collaboration, which was signed in February 2015, with Foundation Medicine to discover and develop precision medicines in oncology.
Drug Research > Drug Discovery & Development > News
Novartis signs collaboration deal with Parvus for diabetes nanomedicine
By PBR Staff Writer
Pharma giant Novartis has acquired the exclusive, worldwide rights for Parvus Therapeutics’ Navacim technology for type 1 diabetes (T1D) treatment.
Drug Research > Drug Discovery & Development > News
Alpine Immune Sciences to merge with Nivalis Therapeutics
Alpine Immune Sciences has agreed to merge with a subsidiary of Nivalis Therapeutics in an all-stock transaction.
Drug Research > Drug Discovery & Development > News
HitGen, Pfizer to build and screen novel DNA-encoded libraries
HitGen has entered into a multi-year research collaboration and license agreement with Pfizer to build and screen novel DNA-encoded libraries (DELs) to potentially discover unique small molecule leads to be used in developing drugs.
Drug Research > Drug Discovery & Development > News
Icon Bioscience submits NDA to FDA for anti-inflammatory drug Dexycu
Icon Bioscience has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its lead pipeline product Dexycu (IBI-10090).
Drug Research > Drug Discovery & Development > News
Lyndra secures $23m funding to develop therapeutic oral delivery platform
Lyndra has secured $23m Series A financing, led by Polaris Partners, with participation from Quark Venture and GF Securities, Yonghua Capital, Healthlink Capital, Suffolk Equity, Partners Healthcare among others.
Drug Research > Drug Discovery & Development > News
BioCryst to explore BCX7353 use in acute HAE attacks
BioCryst Pharmaceuticals revealed its plans to explore a new oral liquid formulation of BCX7353 for the treatment of acute attacks in hereditary angioedema (HAE) patients.
Drug Research > Drug Discovery & Development > News
PureTech Health launches new immuno-oncology programme
PureTech Health has launched a new immuno-oncology programme to develop monoclonal antibodies to target newly discovered immunosuppressive mechanisms in pancreatic cancer and other solid tumours.
Drug Research > Drug Discovery & Development > News
Single dose of live-attenuated Zika vaccine found to protect mice
By PBR Staff Writer
New research has revealed that a single dose of the first live-attenuated Zika vaccine has been found to protect mice against the virus.
Drug Research > Drug Discovery & Development > News
Takeda, NuBiyota to collaborate on microbiome therapeutics
Takeda Pharmaceutical has partnered with NuBiyota to develop Microbial Ecosystem Therapeutic products for gastroenterology (GI) conditions.
Drug Research > Drug Discovery & Development > News
Immune-Onc to partner with University of Texas on novel cancer immunotherapy
Immune-Onc Therapeutics has signed an exclusive license and collaboration agreement with The University of Texas Health Science Center at Houston (“UTHealth”) and The University of Texas Southwestern Medical Center (“UTSW”), two member institutions of The University of Texas System (“UT System”).
Drug Research > Drug Discovery & Development > News
Eisai and Meiji enter into agreement for Parkinson's disease drug in Asian countries
Eisai and Meiji Seika Pharma have entered into a license agreement for the commercialization of safinamide for Parkinson's disease treatment in Japan and Asia.
Drug Research > Drug Discovery & Development > News
Finch and Takeda to jointly develop microbiome therapeutics in IBD
Microbiome engineering company, Finch Therapeutics and Takeda Pharmaceutical have reached a global collaboration agreement for the joint development of FIN-524.
Drug Research > Drug Discovery & Development > News
Aviragen Therapeutics to explore strategic alternatives
Aviragen Therapeutics intends to explore a range of strategic alternatives including a business combination, merger, in-licensing of complementary products, acquisition or any other value-building transaction.
Drug Research > Drug Discovery & Development > News
Sucampo Pharmaceuticals buys rare disease firm Vtesse
Sucampo Pharmaceuticals has acquired rare disease company Vtesse for upfront consideration of $200m.
Drug Research > Drug Discovery & Development > News
106-120 of 4506 results